Fox Chase study: Radiation then tamoxifen after lumpectomy for early-stage breast cancer pts

October 16, 2005

DENVER--Fox Chase Cancer Center researchers say the sequence of tamoxifen and radiation following lumpectomy for early-stage breast cancer patients does not affect disease control, survival or complication rates, but administering tamoxifen concurrently with radiation has negative cosmetic results. These findings of this study, the largest known series of data examining the sequencing of tamoxifen and radiation, were presented today at the 47th Annual Meeting of the American Society for Therapeutic Radiology and Oncology in Denver, Colo.

"Prior to this study, the sequencing of radiation and tamoxifen following lumpectomy had not been well-established," explained Penny Anderson, M.D., a radiation oncologist at Fox Chase Cancer Center in Philadelphia and lead author of the study. "Some studies have suggested a potential negative effect of tamoxifen on radiosensitivity when the drug was administered during radiation treatments, while other studies have not demonstrated an adverse effect."

Anderson's study included 1,088 women with stage I/II breast cancer who underwent breast-conserving surgery and radiation therapy and received adjuvant tamoxifen (with or without chemotherapy) between 1982 and 2004. Of these, 699 patients received tamoxifen after completing radiation (sequential) and 389 patients received tamoxifen during radiation therapy (concurrent).

There were no statistically significant differences observed between the sequential group and the concurrent group for disease control and survival. However, there was a statistically higher rate of excellent/good cosmesis in the sequential group compared to the concurrent group (95 percent versus 88 percent).

"Previous studies have shown that quality-of-life issues such as the appearance of the affected breast after treatment is important to women," said Anderson. "We continue to recommend sequential sequencing of tamoxifen and radiation, but concurrent administration has acceptable outcomes if required by a clinical trial or delay in the time of radiation after surgery or chemotherapy."

Other authors of the study include radiation oncologist Gary Freeman, M.D., and biostatisticians Tianyu Li, Ph.D., and Eric Ross, Ph.D., all of Fox Chase Cancer Center.
-end-
Fox Chase Cancer Center was founded in 1904 in Philadelphia as the nation's first cancer hospital. In 1974, Fox Chase became one of the first institutions designated as a National Cancer Institute Comprehensive Cancer Center. Fox Chase conducts basic, clinical, population and translational research; programs of prevention, detection and treatment of cancer; and community outreach. For more information about Fox Chase activities, visit the Center's web site at www.fccc.edu or call 1-888-FOX CHASE.

Fox Chase Cancer Center

Related Radiation Therapy Articles from Brightsurf:

Pulmonary artery thrombosis a complication of radiation therapy
According to ARRS' American Journal of Roentgenology, the imaging findings of in situ pulmonary artery thrombosis (PAT) associated with radiation therapy (RT) are different from those of acute pulmonary emboli and do not appear to embolize.

New approach for calculating radiation dosimetry allows for individualized therapy
Researchers have developed a simplified process that could enhance personalization of cancer therapy based on a single nuclear medicine scan.

Developing microbeam radiation therapy (MRT) for inoperable cancer
An innovative radiation treatment that could one day be a valuable addition to conventional radiation therapy for inoperable brain and spinal tumors is a step closer, thanks to new research led by University of Saskatchewan (USask) researchers at the Canadian Light Source (CLS).

Travel considerations specified for 177Lu-DOTATATE radiation therapy patients
Researchers and patient advocates have addressed the challenges related to traveling after receiving 177Lu-DOTATATE radiation therapy in a study published in the April issue of The Journal of Nuclear Medicine.

A new way to monitor cancer radiation therapy doses
More than half of all cancer patients undergo radiation therapy and the dose is critical.

AI can jump-start radiation therapy for cancer patients
Artificial intelligence can help cancer patients start their radiation therapy sooner -- and thereby decrease the odds of the cancer spreading -- by instantly translating complex clinical data into an optimal plan of attack.

Towards safer, more effective cancer radiation therapy using X-rays and nanoparticles
X-rays could be tuned to deliver a more effective punch that destroys cancer cells and not harm the body.

Radiation therapy effective against deadly heart rhythm
A single high dose of radiation aimed at the heart significantly reduces episodes of a potentially deadly rapid heart rhythm, according to results of a phase one/two study at Washington University School of Medicine in St.

New mathematical model can improve radiation therapy of brain tumours
Researchers have developed a new model to optimize radiation therapy and significantly increase the number of tumor cells killed during treatment.

Using artificial intelligence to deliver personalized radiation therapy
New Cleveland Clinic-led research shows that artificial intelligence (AI) can use medical scans and health records to personalize the dose of radiation therapy used to treat cancer patients.

Read More: Radiation Therapy News and Radiation Therapy Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.